Arca
Skip to content
Tools
Tools

HDAC8: Histone deacetylase 8

Histone deacetylase that catalyzes the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on HDAC8, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved0

    Phase 30

      Phase 21

      • Mocetinostat

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        MocetinostatPhase 2Mirati TherapeuticsSmall moleculeInhibitorHistone deacetylase 8 inhibitor2

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
        Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent RhabdomyosarcomaMocetinostatPhase 1Active, not recruitingJonsson Comprehensive Cancer CenterMar 6, 2020
        Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.MocetinostatPhase 1Active, not recruitingMemorial Sloan Kettering Cancer CenterJul 18, 2017

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Cornelia de Lange syndrome0.83
        • Wilson-Turner syndrome0.59
        • Neoplasm0.56
        • Plasma cell myeloma0.55
        • Hereditary disease0.54
        • Peripheral T-cell lymphoma, not otherwise specified0.52
        • Intellectual disability0.50
        • Mature T-cell and NK-cell non-Hodgkin lymphoma0.50
        • Primary cutaneous T-cell non-Hodgkin lymphoma0.49
        • T-cell non-Hodgkin lymphoma0.48
        • 3q26 microduplication syndrome0.46

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3192, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q9BY41, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.